Patent ID: 7772181

Claim:
A personal care composition comprising a modified variant Bowman Birk Protease Inhibitor (BBPI), wherein said modified variant BBPI comprises a BBPI scaffold selected from the group consisting of: BBI (SEQ ID NO: 13), BBIt (SEQ ID NO:185), BBI-AV (SEQ ID NO:186), BBIt-AV (SEQ ID NO:187), BBIt-VEGK (SEQ ID NO:640), BBIt-VEGT (SEQ ID NO:641), BBIt-VEGKD (SEQ ID NO:642), BBdb (SEQ ID NO:449), BBsb3 (SEQ ID NO:450), BBtc (SEQ ID NO:451), BBdb-AV (SEQ ID NO:452), BBsb3-AV (SEQ ID NO:453) and BBtc-AV (SEQ ID NO:454), wherein the second protease inhibitory loop of the BBPI scaffold is replaced with a binding peptide selected from the group consisting of a vascular endothelial growth factor (VEGF) binding peptide, a fibroblast growth factor-5 (FGF) binding peptide, a transforming growth factor β (TGF) binding peptide and a tumor necrosis factor α (TNF) binding peptide; and wherein the backbone of the BBPI scaffold is substituted at one or more amino acid positions selected from the group consisting of positions equivalent to positions 1, 4, 5, 11, 13, 18, 25, 27, 29, 31,38, 40, 50, 52, 55 and 65 of SEQ ID NO:187; wherein the substitution at position 1 is to A or C, the substitution at position 4 is to V, the substitution at position 5 is to P or A, the substitution at position 11 is to G, the substitution at position 13 is to Y, I, F, M, L, V, K or R, the substitution at position 18 is to I, V or L, the substitution at position 25 is to K, N, W, I, A, R or L, the substitution at position 27 is to R, K, V, A or Q, the substitution at position 29 is to R, K, P or E, the substitution at position 31 is to Q, H, E, A, R, W, K or T, the substitution at position 38 is to N, K or R, the substitution at position 40 is to H, K, Q, R or Y, the substitution at position 50 is to R, Q, K, T, V, M or S, the substitution at position 52 is to K, T, R, Q, L, H, A, M, S or E, the substitution at position 55 is to M and the substitution at position 65 is to E, Q or D.